{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:38:08Z","timestamp":1792805888037,"version":"4.5.0"},"reference-count":11,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: In the metastatic setting, cancer patients may not benefit from standard care regimes and their diseases undergo drug resistance due to tumour cell heterogeneity and genomic landscape complexity. In recent years, there have been several attempts to personalise the diagnostic-therapeutic path and to propose novel strategies based on not only histological test results but also on each patient\u2019s clinical history and molecular biology. Profiling molecular tests allows physicians to investigate the single tumour genomic landscape and to promote targeted approaches. The Molecular Tumour Board (MTB) is a multidisciplinary committee dedicated to selecting individualised and targeted therapeutic strategies appropriate for patients suffering from diseases that present resistance to standard care. Materials and Methods: Our MTB settled in \u201cAzienda Ospedaliero Universitaria delle Marche\u201d, Ancona (AN), Italy, and includes oncologists, molecular biologists, geneticists, and other specialists. Clinical cases are referred by physicians to the MTB, through the Cancer and Research Centre of the Marche Region (CORM), through a telemedicine platform. Four possible molecular profiles are available: FoundationOne\u00ae CDx e FoundationOne\u00aeLiquid CDx and two local Next Generation Sequencing (NGS) panels, with 16 DNA genes and 10 RNA genes respectively. The resulting genetic mutations and their analyses are evaluated by all the members of the Board and a report for each patient is provided with medical recommendations. Results: from June 2021 to May 2023, we collected data from 97 referral patients (M: 49, F: 48). The mean age was 60.6 years (range 22\u201383 years). 90 cases were approved for testing. Only seven patients were not eligible for genomic profiling. In two patients who were eligible, molecular profiling was not performed because a tissue sample was not available. Off-label therapy was recommended for three patients. 5% of cases (5\/88) showed addressable driver mutations associated with an existing targeted therapy and were immediately enrolled. Conclusions: MTB presents a powerful tool for offering precise medical goals. Our Department of Clinical Oncology also takes advantage of the important role of multidisciplinary teams, through the establishment of CORM and MTB meetings, within which there is the chance to perform NGS-based analyses. It will be important in the future to implement the use of genomic profiling to improve personalised care and to guide the choice of suitable therapies and more appropriate management of patients.<\/jats:p>","DOI":"10.3390\/jcm12206666","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T12:59:48Z","timestamp":1697893188000},"page":"6666","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine"],"prefix":"10.3390","volume":"12","author":[{"given":"Zelmira","family":"Ballatore","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, AOU delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bozzi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cardea","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-0935","authenticated-orcid":false,"given":"Francesco Domenico","family":"Savino","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Migliore","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tarantino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AOU delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Chiodi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ambrosini","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5198-8387","authenticated-orcid":false,"given":"Gaia","family":"Goteri","sequence":"additional","affiliation":[{"name":"Anatomia Patologica, AOU delle Marche, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-4898","authenticated-orcid":false,"given":"Alessandra","family":"Filosa","sequence":"additional","affiliation":[{"name":"Anatomia Patologica, AOU delle Marche, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barbisan","sequence":"additional","affiliation":[{"name":"Anatomia Patologica, AOU delle Marche, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bartoli","sequence":"additional","affiliation":[{"name":"Anatomia Patologica, AOU delle Marche, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Papa","sequence":"additional","affiliation":[{"name":"Quality, Risk Management and Health Technology Innovation Unit, Department of Staff, AOU delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9529-2960","authenticated-orcid":false,"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AOU delle Marche, 60126 Ancona, Italy"},{"name":"Medical Oncology, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2012.46.8934","article-title":"Genomics-driven oncology: Framework for an emerging paradigm","volume":"31","author":"Garraway","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.trecan.2020.05.008","article-title":"Molecular Tumor Boards in Clinical Practice","volume":"6","author":"Luchini","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.mjafi.2021.06.021","article-title":"Precision medicine: Concept and tools","volume":"77","author":"Naithani","year":"2021","journal-title":"Med. J. Armed Forces India"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ygyno.2016.02.021","article-title":"Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers","volume":"141","author":"Hirshfield","year":"2016","journal-title":"Gynecol Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/d41586-020-02673-y","article-title":"Precision oncology","volume":"585","author":"Hodson","year":"2020","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2000508","DOI":"10.1200\/PO.20.00508","article-title":"Real-World Data from a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine","volume":"6","author":"Charo","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2013-0405","article-title":"Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience","volume":"19","author":"Schwaederle","year":"2014","journal-title":"Oncologist"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Agostinelli, V., Cognigni, V., Lunerti, V., Cicoli, C., Ricci, G., Papa, R., and Berardi, R. (2022). Diagnostic and therapeutic care pathways of cancer patients: A model of multidisciplinary management and patient-tailored healthcare at University Hospital in Italy. Hosp. Adm. Med. Pract., 1.","DOI":"10.54844\/hamp.2022.0027"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2100524","DOI":"10.1200\/PO.21.00524","article-title":"Molecular Tumor Board-Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial","volume":"6","author":"Miller","year":"2022","journal-title":"JCO Precis. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/20\/6666\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:09:36Z","timestamp":1760130576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/20\/6666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,21]]},"references-count":11,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["jcm12206666"],"URL":"https:\/\/doi.org\/10.3390\/jcm12206666","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,21]]}}}